The University of Texas MD Anderson Cancer Center
Department of Leukemia
My clinical and research interests focus on inherited predispositions to hematologic malignancies. This interest led to the development of one of the first dedicated clinics for evaluation of families with hematologic malignancies in the country (Hereditary Hematologic Malignancy Clinic—HHMC) in April 2014. The HHMC provides research-based opportunities for scientific discovery through whole exome sequencing families with a strong history of hematologic malignancies including the potential for novel gene discovery. My research in the evolving clinical phenotype and treatment outcomes of IDH1 and IDH2 mutations in myeloid malignancies has yielded numerous publications and national/international IDH-inhibitor trials. My expertise in myeloid malignancy metabolomics has also driven my research related to therapeutic targeting of glutamine metabolism in myelodysplastic syndrome.
Education & Training
M.D. - University of Michigan - 2006